Objective-The Ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) is a scaffolding protein known to regulate ion homeostasis in the kidney and intestine. Previous work showed that EBP50 expression increases after balloon injury in rat carotids. This study was designed to determine the role of EBP50 on vascular smooth muscle cells (VSMC) proliferation and the development of neointimal hyperplasia. Methods and Results-Wire injury was performed in wild type (WT) and EBP50 knockout (KO) mice. Two weeks after injury, neointima formation was 80% lower in KO than in WT mice. Proliferation of KO VSMC was significantly lower than WT cells and overexpression of EBP50 increased VSMC proliferation. Akt activity and expression of S-phase kinase protein2 decreased in KO cells resulting in the stabilization of the cyclin-dependent kinase inhibitor, p21 cip1 . Consequently, KO cells were arrested in G 0 /G 1 phase. Consistent with these observations, p21 cip1 was detected in injured femoral arteries of KO but not WT mice. No differences in apoptosis between WT and KO were observed. Conclusion-EBP50 is critical for neointima formation and induces VSMC proliferation by decreasing S-phase kinase protein2 stability, thereby accelerating the degradation of the cell cycle inhibitor p21 cip1 . (Arterioscler Thromb Vasc Biol. 2012;32:33-41.) Key Words: EBP50 Ⅲ Skp2 Ⅲ p21cip1 Ⅲ proliferation Ⅲ smooth muscle Ⅲ NHERF1 N eointimal hyperplasia is a common complication of atherosclerosis and surgical vascular interventions, particularly angioplasty. Although it is clear that neointima formation following arterial injury originates from several cellular processes, including the initial inflammatory response, increased matrix production and migration of vascular smooth muscle cells (VSMC), the proliferation of VSMC is a major contributing factor. 1 Consequently, several studies examined how manipulation of the expression of molecules involved in cell cycle progression affects neointimal hyperplasia. Of particular interest in this respect are the cyclindependent kinase inhibitors p21 cip1 and p27 kip1 . Studies in animal models clearly demonstrated that increased expression of p21 cip1 in vessels decreases the progression and severity of neointima formation following injury. p21 cip1 is undetectable in uninjured human and porcine arteries but its expression increases following injury and inversely correlates with VSMC proliferation. 2 Adenoviral delivery of p21 cip1 inhibits neointimal thickening in rats and pigs. 2,3 Moreover, p21 cip1 mediates the antiproliferative effect of nitric oxide on VSMC. 4 However, 2 studies show that reduction of p21 cip1 does not increase neointimal hyperplasia in animal models. 5, 6 Similar to p21 cip1 , p27 kip1 exerts important effects on disease progression. Overexpression of p27 kip1 in pig arteries reduced intima formation by 50%. 7 Increased expression of p27 kip1 attenuates neointima formation, 7 and expression of a dominant negative form of Skp2 inhibits intimal hyperplasia by increasing p27 kip1 . 8 The upregulation of p27 kip1 accounts, at least in part, for the remarkable inhibition observed on adenoviral delivery of a parathyroid hormone-related protein (PTHrP) devoid of the nuclear localization signal. 9 The ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50), also known as NHERF1, is a cytoplasmic adaptor protein involved in the regulation of a variety of membrane receptors, channels, and transporters. 10 EBP50 contains 2 tandem PDZ motifs that mediate protein-protein interactions. 11 In addition, EBP50 possesses a C-terminal merlinezrin-radixin-moesin binding motif that tethers the protein to the cytoskeleton. 11 EBP50 is highly expressed in the kidney and the small intestine, where it exerts important regulatory functions on electrolyte transporters. The role of EBP50 on vascular function is largely unknown. We showed that in rat carotid arteries EBP50 expression is restricted to the endothelium and the adventitia with little (but detectable)
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The studies reported here establish important effects of EBP50 in the response of VSMC to injury. Specifically, EBP50 is critical for neointima formation and regulates VSMC proliferation by decreasing the stability of the cell cycle inhibitor p21 cip1 .
Materials and Methods
Detailed methodologies for femoral artery injury, cell culture and transfection, proliferation and fluorescence-activated cell sorting assays, immunohistochemical staining and microscopy analysis, Western blot analysis, RT-PCR, and statistical methods are described in the Supplemental Methods, available online at http://atvb.ahajournals.org.
Experimental Animals and Surgeries
Animal studies were performed on 10-week-old wild type (WT) C57BL/6 mice and EBP50 knockout (KO) littermates. Injury was performed with a 0.014 " guide wire passed within the femoral artery 3 times. The right femoral artery was used as a control uninjured artery. Femoral arteries were removed 2 weeks after surgery. All animal procedures were approved by the University of Pittsburgh Institutional Animal Care and Use Committee.
Immunofluorescence and Immunohistochemistry
Femoral arteries (both control and injured) were excised from WT and KO mice, fixed with 4% paraformaldehyde and embedded in OCT Tissue-Tek (Sakura Finetek). Sections were analyzed by immunofluorescence or immunohistochemistry using antibodies against ␣-actin, CD31, EBP50, Ki67, p21 cip1 , and p27 kip1 . For morphometric analysis, frozen femoral artery sections from WT and KO mice were selected at 100-m intervals and stained using an Elastic Stain Kit (Sigma). Images were analyzed with the Image J software (National Institutes of Health). Immunofluorescence analysis of cultured cells was performed as described. 12, 13 Primary VSMC Culture and Transfection Primary VSMC were isolated from abdominal aortic explants and cultured in Dulbecco's modified eagle media containing 10% fetal bovine serum (FBS) in 5% CO 2 at 37°C. All experiments were performed with cells between passages 3 and 15. Cells were transfected with siRNA for EBP50 and p21 cip1 (0.1 mol/L) using DharmaFECT Duo transfection reagent (Dharmacon, Thermo Scientific) and used for experiments 72 hours after transfection. Yellowfluorescent protein (YFP)-tagged EBP50 was introduced in primary VSMC by electroporation. Lentiviral shRNA vectors specific to mouse EBP50 and GFP-expression control lentivirus were prepared by the Lentiviral Facility at the University of Pittsburgh Cancer Institute. Aliquots of virus were used to infect exponentially growing cells. Cells were used 72 hours after infection.
Western blot analysis, immunoprecipitation, quantitative RT-PCR, and proliferation assays were performed essentially as described. 12, 13 
Results

Role of EBP50 on Neointima Formation
The observation that EBP50 expression increases after endoluminal injury 12 suggests that it contributes to neointimal hyperplasia. To determine directly if this is the case, wire injury was performed in 10-week-old WT and KO male littermate mice. As shown in Figure 1A and 1B, exuberant neointima formed in WT mice (top panels) 2 weeks after injury. In contrast, neointima formation was significantly reduced in KO mice (lower panels). The histomorphometric parameters of the injured vessels are shown in Figure 1D . The neointimal area in WT mice was significantly larger than in KO mice, whereas the areas of the media were not different. Consequently, KO mice displayed an 80% reduction in neointima/media ratio compared to WT mice (2.54Ϯ0.58 in WT mice versus 0.53Ϯ0.25 in KO mice, Pϭ0.02, Nϭ5) ( Figure 1C ). To better characterize the cellular composition of the vessels, control and injured femoral arteries from WT and KO mice were immunostained for CD31 (to visualize endothelial cells) and ␣-smooth muscle actin (to visualize smooth muscle cells). No major differences were observed in uninjured vessels from WT and KO mice ( Figure 1B , left panels). Two weeks after angioplasty, the neointima in WT and KO vessels was predominantly composed of cells expressing ␣-smooth muscle actin ( Figure 1B in green) and a complete endothelial lining was observed ( Figure 1B in red) . Cells in the adventitia did not express ␣-smooth muscle actin, compatible with the predominant presence of fibroblasts. The expression of EBP50 in injured vessels was determined by immunofluorescence ( Figure 1E and F). Consistent with previous observations in rat carotid arteries, 12 EBP50 expression in the intima of injured femoral arteries was significantly higher than the media (ratio intima/media 3.2Ϯ0.3, PϽ0.004, Nϭ4). A similar increase was determined in the adventitia (ratio adventitia/media 4.3Ϯ1.3, PϽ0.03, Nϭ4).
EBP50 Affects VSMC Proliferation
The preceding observations raise the possibility that EBP50 contributes to neointimal hyperplasia by increasing VSMC proliferation, a key cellular event leading to neointima formation. VSMC proliferation in vivo following injury was determined by immunodetection of Ki67 ( Figure 1G , 1H, and 1I). The percentage of Ki67-positive cells in the intima was significantly reduced in vessels from KO mice compared to WT vessels ( Figure 1H ). The number of Ki67-positive cells in the adventitia of WT and KO arteries was not significantly different ( Figure 1I ). To further characterize the effect of EBP50 on VSMC proliferation, we used primary VSMC isolated from WT and KO littermates. Western blot analysis verified that EBP50 was expressed in WT cells but not in KO cells (Figure 2A ). Thymidine incorporation assays and cell counting demonstrated that proliferation of KO cells was significantly lower than that of WT cells ( Figure 2B and C). Similarly, the proliferation of WT cells was significantly reduced by inhibition of EBP50 expression with siRNA ( Figure 2D ). Conversely, increasing expression of EBP50 (by electroporation) increased WT VSMC proliferation ( Figure 2E ).
To determine which cell cycle phase is affected by EBP50, the cell cycle distribution of WT and KO cells grown in 10% FBS was determined by fluorescence-activated cell sorting analysis. As shown in Figure 3A 
EBP50 Regulates p21 cip1 Expression
Next, the expression of the critical regulators of the G 1 -S transition was determined in WT and KO cells. Western blot analysis indicated equal expression of cyclin E and cyclin D1 (Supplemental Figure IB) . Similarly, the expression of cdk4 was unchanged in WT and KO cells. A small, not statistically significant, reduction in cdk2 and cyclin D3 expression was observed in KO cells (Supplemental Figure IB) . In striking contrast, the expression of the cyclin-dependent kinase inhibitor p21 cip1 was 8-fold higher in KO cells compared to WT ( Figure 3B and C). Identical observations were made in independent preparations from 2 other mice (Supplemental Figure IC) . Quantitative RT-PCR showed that the mRNA levels of p21 cip1 were similar in WT and KO cells ( Figure  3D ), suggesting that EBP50 regulates p21 cip1 expression posttranslationally. Consistent with this interpretation, the expression of p53, a well-known upstream regulator of p21 cip1 transcription, was unchanged in KO cells ( Figure 3B ). In addition, the regulation of p21 cip1 expression by EBP50 was fully recapitulated in Chinese Hamster Ovary cells following recombinant expression of myc-tagged p21 cip1 and EBP50 under the control of CMV promoters (Supplemental 
Figure ID). The expression of p27
kip1 , another inhibitor of the G1-S transition, was equal in WT and KO cells ( Figure 3B and 3D), indicating that the regulation of p21 cip1 by EBP50, and the consequent effects on cell cycle progression, are specific. To determine if the expression of p21 cip1 is critical for the different proliferation of WT and KO VSMC, its expression in KO cells was inhibited by siRNA. This treatment resulted in an 80% reduction in p21 cip1 protein ( Figure  3E ). Decreasing p21 cip1 expression significantly accelerated KO cell proliferation ( Figure 3E ), indicating that the expression level of this cell cycle inhibitor is sufficient to regulate SMC growth. 14 Immunofluorescence analysis of KO VSMC demonstrated high expression and clear nuclear localization of p21 cip1 (Supplemental Figure IIA) . In contrast, p21 cip1 expression was significantly reduced in WT VSMC (Supplemental Figure IIA) . Total levels of p21 cip1 increased in both WT and KO cells on treatment with the proteasome inhibitor MG132. The increase in WT cells was significantly higher than in KO cells, suggesting an increased degradation rate of p21 cip1 in WT cells (Supplemental Figure IIB and IIC) . Similarly, the total levels of p27 kip1 increased on treatment with MG132, but the effect was similar in WT and KO cells (Supplemental Figure IIC) . To determine whether the expression of EBP50 correlates with p21 cip1 degradation, p21 cip1 was visualized in KO VSMC transfected with YFP-EBP50. p21 cip1 was detected in the nucleus of more than 90% of KO VSMC. In contrast, only 50% of cells expressing YFP-EBP50 were also positive for p21 cip1 (Pϭ0.0001) (Supplemental Figure III) . Collectively, these experiments show that p21 cip1 levels are lower in cells expressing EBP50, and that EBP50 increases degradation of p21 cip1 . Indeed, the half-life of p21 cip1 (determined in the presence of cyclohexamide) was reduced in WT cells compared to KO cells (45Ϯ8 minutes in WT cells versus 82Ϯ16 minutes in KO cells) ( Figure 4A and Supplemental Figure IV ).
EBP50 Regulates Skp2 Expression
The reduced degradation of p21 cip1 in EBP50 KO cells suggests that EBP50 may regulate the activity of the Skp1/ Cullin-1/F-box (SCF) E3-ligase responsible for p21 cip1 degradation. 15 Of particular interest is the F-box protein Skp2 that directs recognition of p21 cip1 by the SCF complex. 16 The expression of Skp2 was reduced in primary VSMC from KO mice ( Figure 4B ). Similar reduction in Skp2, accompanied by a corresponding increase in p21 cip1 was observed in WT cells in which EBP50 expression was inhibited by 2 distinct lentivirus expressing shRNA against EBP50 ( Figure 4C , left panel). Conversely, expression of YFP-EBP50 in VSMC increased Skp2 and reduced p21 cip1 ( Figure 4C , right panel). The relation between EBP50 and Skp2 expression was established in distinct VSMC preparations in which EBP50 expression was reduced to various degrees by shRNA. As shown in Figure 4D , a direct and significant correlation was found between the expression of EBP50 and that of Skp2 in primary VSMC. The stability of Skp2 (determined in the presence of cyclohexamide) was reduced in KO cells compared to WT cells ( Figure 4E ). In contrast, mRNA for Skp2 was not different in WT and KO VSMC ( Figure 4F ), indicating that EBP50 predominantly regulates Skp2 expression posttranslationally. To determine if the expression level of Skp2 is critical to VSMC proliferation, KO VSMC were transiently transfected with Flag-Skp2. Immunofluorescence analysis showed the clear localization of Flag-Skp2 in the nucleus (Supplemental Figure V) . In these cells, proliferation (determined by costaining for BrDU) was significantly increased ( Figure 4G) .
Collectively, these experiments show that EBP50 regulates Skp2 levels and, consequently, p21 cip1 stability. However, we found no difference in p27 kip1 expression in WT and KO cells ( Figure 3B ). This suggests the possibility that p27 kip1 degradation is less sensitive to modest variations in Skp2 expression than p21 cip1 . Indeed, overexpression of Skp2 in KO VSMC efficiently decreased both p21 cip1 and p27 kip1 (Supplemental Figure VI) . The reduction of Skp2 expression in EBP50 KO cells prompted us to determine if, in addition to the reduction in cell proliferation, other phenotypes observed on deletion of Skp2 17 were also evident in on EBP50 knockout. The body weight of EBP50 KO mice was reduced compared to WT littermates up to seven weeks of age, after which the mice were of similar size (Supplemental Figure VIIA) . Skp2 null cells are enlarged compared to normal cells. 17 Consistent with these observations, EBP50 KO VSMC were larger than WT cells (Supplemental Figure VIIB) .
EBP50 Regulates Akt Activity
Akt is a major transducer of mitogenic signals in a variety of cells. 18 Akt is activated by arterial injury and contributes to neointima formation. 19, 20 Because EBP50 regulates growth factors signaling and Akt activity in a cell-specific manner, [21] [22] [23] [24] [25] [26] we determine Akt activity in WT and KO VSMC. As shown in Figure 5A , serum stimulation of previously starved WT cells induced robust phosphorylation of Akt after 5 and 30 minutes. In contrast, the response of KO cells to the same stimulus was blunted. Similar reduction in Akt activation was determined in KO cells on stimulation with EGF ( Figure 5B ). Moreover, as reported previously, EBP50 coimmunoprecipitated with Akt ( Figure 5C and Supplemental Figure VIII) , an interaction that potentiates Akt activation. 26 The expression and cellular localization of phosphatase and tensin homolog (PTEN), a regulator of the PI3K/Akt pathway known to interact with EBP50, 23, 25 was not different in WT and KO VSMC (Supplemental Figure IX) . Collectively, these experiments show that EBP50 potentiates Akt activity in VSMC by regulating growth factor receptor signaling and by directly interacting with Akt. Inhibition of Akt by LY294002 and Akt1/2 kinase inhibitor (AKTI) blocked VSMC proliferation both in WT and KO cells ( Figure 5D ). Akt inhibition was equally effective in reducing proliferation (assessed by BrDU incorporation) of naïve VSMC and of cells overexpressing YFP-EBP50 ( Figure 5E and Supplemental Figure  X) , indicating that the mitogenic action of EBP50 is Akt-dependent. The preceding observations raise an intriguing question. In most mammalian cells, Akt regulates Skp2 expression both transcriptionally and by increasing its stability. 27, 28 The latter effect has been attributed to the direct phosphorylation of Skp2 by Akt. 27, 28 However, Akt does not phosphorylate mouse Skp2. 27 Thus, the mechanisms by which Akt regulates Skp2 expression in mouse cells, and the possible involvement of EBP50, remain unclear. Consistent with other reports, 14, 27, 28 inhibition of Akt with either LY294002 or AKTI reduced Skp2 expression in VSMC maintained in serum-supplemented media (Figure 5F ), confirming the key role of Akt on Skp2 transcription. Furthermore, immunoprecipitation assays show that EBP50 constitutively interacts with Skp2 and this interaction is increased by expression of a constitutively active form of Akt (Myr-Akt) ( Figure 5G ). This observation suggests a possible mechanism for the observed stabilization of Skp2 in EBP50 expressing mouse cells.
EBP50 Regulates p21 cip1 Expression In Vivo
The preceding observations in primary VSMC clearly indicate that in the absence of EBP50 the stability of p21 cip1 is increased resulting in inhibition of cell proliferation. To determine if similar regulation occurs in vivo, the expression of p21 cip1 was determined in the femoral arteries of WT and KO mice. p21 cip1 was undetectable in control uninjured vessels (Figure 6 left panels) . Similarly, little expression of p21 cip1 was observed in injured vessels of WT mice. In contrast, p21 cip1 was present both in the neointima and in the adventitia of femoral arteries of KO mice 2 weeks after injury ( Figure 6 , right panels). Consistent with the findings in cells, analysis of p27 kip1 expression in WT and KO femoral arteries revealed similar expression in both control and injured vessels (Supplemental Figure XI) .
VSMC growth is the balance between proliferation and apoptosis, and p21 cip1 plays important roles on both cellular events. To determine if the different expression of p21 cip1 in WT and KO mice affects VSMC survival, apoptosis in injured vessels was determined by TUNEL staining. The number of apoptotic cells in the intima and media of WT and KO vessels 2 weeks after injury was very low (approximately 0.25% of total cells) and not different between mice (Supplemental Figure XIIA) . To assess possible differences in apoptosis on cellular stress, TUNEL assays were performed in WT VSMC and in cells in which EBP50 expression was inhibited by shRNA following 24 hours of serum starvation. Again, no differences in TUNEL staining were observed between control and shRNA-treated cells (Supplemental Figure XIIB) . These observations suggest that differences in cell survival do not contribute to the reduced neointima formation in KO mice. 
Discussion
The major finding in this report is the remarkable effect that the scaffolding protein EBP50 has in the development of neointimal hyperplasia following arterial injury. Two key and novel observations are presented. First, genetic ablation of EBP50 in mice results in almost complete inhibition of restenosis following endothelial denudation. Second, EBP50 exerts important effects on the cell cycle of VSMC, in particular by regulating the expression of Skp2 and the stability of the cell cycle inhibitor p21 cip1 . EBP50 is widely expressed and its function in the regulation of electrolyte transport has been well-characterized in the kidney and intestine. 29, 30 The original observation that EBP50 expression increases in the neointima formed after endothelial denudation in rat carotid arteries, 12 replicated here in murine femoral arteries, suggested its possible involvement in the response of VSMC to injury. The lack of neointimal hyperplasia observed in EBP50 knockout mice is, to the best of our knowledge, the first evidence of the actions of EBP50 on vascular remodeling.
The reduced cell proliferation of KO cells was accompanied by cell cycle arrest in the G 0 /G 1 phase. Examination of the principal regulators of the G 1 -S transition clearly indicated that the major protein affected by EBP50 is p21 cip1 . p21 cip1 levels were increased in both cultured KO cells and in the injured vessels of KO mice. The role of p21 cip1 in regulating VSMC proliferation and neointima formation has been documented by several investigators. In particular, increased expression of p21 cip1 in vessels resulted in diminished hyperplasia following injury, 2,7 a result fully consistent with the observations in EBP50 KO mice. Yet, neointima formation is not increased in p21 cip1 knockout mice 5 and increased expression of the transcription factor Ying-Yang 1 inhibits neointimal hyperplasia while reducing p21 cip1 expression. 6 Collectively, these observations indicate that although p21 cip1 is competent to reduce VSMC proliferation and inhibit neointima formation, its absence does not necessarily promote these events, suggesting the existence of compensatory effects from other cell-cycle controlling proteins (such as p27 kip1 ). Interestingly, the regulation of p21 cip1 by EBP50 occurs entirely posttranslationally. This is supported by several lines of evidence. The mRNA levels of p21 cip1 and the expression of p53, the major regulator of p21 cip1 transcription, 31 degradation. This process is dependent on the action of the E3 ubiquitin ligase complex consisting of Cullin-1, Skp1, and RBX1, as well as Skp2, which regulates substrate recognition. 15, 16 We show that ablation of EBP50 induces a marked decrease in Skp2 and, consequently, stabilization of p21 cip1 in cultured cells and in vivo. Conversely, EBP50 overexpression increases Skp2 and decreases p21 cip1 levels in VSMC. Consistent with these findings, adenoviral delivery of a dominant negative form of Skp2 reduced VSMC proliferation and neointima formation in rats. 8 Several studies demonstrated that the PI3K/Akt pathway is a major regulator of Skp2 expression. 14, 27, 28, 32 Indeed, complete inhibition of Akt abrogated Skp2 expression in primary VSMC. We did not detect differences in Skp2 mRNA between WT and KO cellspossibly indicating that the level of Akt signaling in KO cells is sufficient to fully induce gene expression. However, the stability of Skp2 in WT cells was increased. Interestingly, direct phosphorylation of Skp2 by Akt, leading to cytoplasmic retention and stabilization of Skp2, 27, 28 does not occur in mice because Ser72, the site of phosphorylation, is a Gly in the murine Skp2. It should be noted that the importance of phosphorylation of Ser72 for the cellular localization of Skp2 is still controversial. 33 Our observations indicate that a different mechanism mediates Akt-dependent regulation of Skp2. The interaction between EBP50 and Skp2 and the potentiation of this interaction by a constitutively active Akt provide a possible explanation for the regulation of Skp2 stability by Akt in mouse cells. Further studies are required to establish the molecular events underlying the effect of Akt on Skp2 stability in murine systems.
EBP50 deficiency attenuates Akt activity in primary VSMC. This regulation occurs at several levels. First, EBP50 interacts constitutively with Akt and increases Akt activation. 26 Second, EBP50 increases the function of the receptors for epidermal growth factor and platelet-derived growth factor, 2 major activators of Akt signaling in VSMC. 21, 22 EBP50 has been shown to regulate membrane localization, and therefore activity, of the PI3K inhibitor PTEN in glioblastoma cells. 23 However, we detected no differences in PTEN expression and localization in VSMC from WT and KO mice. It is interesting to observe that the effect of EBP50 . Expression of p21 cip1 in mouse femoral arteries. Sections from uninjured femoral artery (left panels) or 2 weeks after wire injury (middle panels) from wild type (WT) (upper panels) and knockout (KO) (lower panels) mice were stained for p21 cip1 (in brown). Shown on the right are higher magnification pictures of the dotted areas. The external elastic lamina is indicated by an arrow, N, the neointima; A, the adventitia. The expression of p21 cip1 is evident in femoral arteries from KO mice two weeks after injury.
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on proliferation is remarkably tissue-and cell-specific. EBP50 is overexpressed in glioblastomas, 34 hepatocellular, 35 and breast carcinomas. 36 Yet, the direction of the effect of EBP50 on cell growth is variable. Although in breast cancer cells and in embryonic fibroblasts EBP50 inhibits cell proliferation, 37, 38 in biliary epithelial cells, as in VSMC, EBP50 stimulates cell growth. 39 EBP50 regulates a variety of molecules involved in cell growth, including growth factor and G protein-coupled receptors, ␤-catenin and PTEN. Therefore, whether EBP50 stimulates or inhibits proliferation depends on the relative importance of these signaling pathways. We show here that the PI3K/Akt/Skp2/p21 cip1 is the major pathway mediating the proliferative effect of EBP50 on VSMC. In contrast, the effect of EBP50 on adventitial cells, predominantly fibroblasts, was not different between WT and KO mice.
EBP50 does not alter the regulation of p27 kip1 in VSMC, consistent with observations made in clonal rat A10 cells. 12 This finding is somewhat puzzling because, like p21 cip1 , p27 kip1 is subject to regulation by Akt and ubiquitin ligase complexes. 40 We observed that p27 kip1 was actively degraded in both WT and KO cells. This suggests the possibility that p27 kip1 degradation is less sensitive to variations in Akt signaling and Skp2 expression than p21 cip1 . It is important to note that in the primary cultures used in these studies neither Akt signaling nor Skp2 expression were entirely abrogated or overactivated. In fact, overexpression of Skp2 in WT VSMC reduced both p21 cip1 and p27 kip1 . In addition, p21 cip1 and p27 kip1 are targeted by more than 1 E3 ligase and by different kinases. 40 It is also possible that EBP50 regulates the ability of Skp2 to specifically recognize and discriminate substrates for degradation. Determining the exact molecular mechanisms underlying the effect of EBP50 on substrate recognition by Skp2 requires further investigation.
In summary, we describe the identification of the scaffolding protein EBP50 as a key regulator of vascular remodeling. EBP50 is required for neointima formation following endoluminal arterial injury in mice and, by controlling Skp2 expression and the stability of p21 cip1 , exerts important actions on cell cycle progression of VSMC. These findings reinforce the emerging importance of scaffolding and adaptor proteins as major regulators of physiological and pathological events.
